Significant Customer and Geographic Information - Concentration Risk (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Merck | Sales | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	28.00%	47.00%	29.00%
Merck | Accounts Receivable | Credit Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	31.00%	54.00%
GSK | Sales | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage		22.00%	20.00%
Novartis | Sales | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	14.00%
Novartis | Accounts Receivable | Credit Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	15.00%
Nestlé | Sales | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	15.00%
Exela | Sales | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage			12.00%
Exela | Accounts Receivable | Credit Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	14.00%
Tate & Lyle | Sales | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	11.00%
Tate & Lyle | Accounts Receivable | Credit Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	16.00%
Pfizer | Accounts Receivable | Credit Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage		16.00%